According to fluorescent in situ hybridization, t(11;14) is the most common cytogenetic abnormality in amyloid light-chain (AL) amyloidosis, but its prevalence in patients with AL amyloidosis and concurrent multiple myeloma (MM) remains unknown. We aimed to examine the prevalence of t(11;14) and the differences in clinical characteristics of patients with t(11;14) who had AL amyloidosis with or without concurrent MM. We retrospectively analyzed 40 patients with AL amyloidosis between January 2008 and January 2018 at our institution. The prevalence of t(11;14) was significantly higher in patients with AL amyloidosis alone compared with those with concurrent MM (56.5% vs. 17.6%; P = 0.022). This study suggests that AL amyloidosis patients with concurrent MM have a lower prevalence of t(11;14) than those without MM and that the presence of t(11;14) may be associated with poor prognosis, irrespective of the presence or absence of MM.
Introduction
Amyloid light-chain (AL) amyloidosis is a rare plasma cell disorder caused by extracellular deposition of misfolded immunoglobulin light chains, which causes end-organ failure (1, 2) . Patients with AL amyloidosis can also have myeloma-defining events such as hypercalcemia, renal failure, anemia and lytic bone lesions (CRAB criteria), which are attributable to clonal proliferation of plasma cells. These patients are considered to have concurrent multiple myeloma (MM). The survival of patients with both AL amyloidosis and concurrent MM is lower than those with AL amyloidosis alone (3) . In MM, detection of cytogenetic abnormality by interphase fluorescence in situ hybridization (iFISH) is essential because of the impacts on prognosis and disease characterization. High-risk cytogenetic abnormalities such as t (4;14) , del(17p) and t (14;16) are key elements of the Revised International Staging System, and t (11;14) is associated with high prevalence of light-chain-only MM (4, 5) .
Cytogenetic evaluation in AL amyloidosis is less well studied because of the low percentage of clonal plasma cells in the bone marrow and low prevalence of the disease. t (11;14) is reported to be the most common cytogenetic abnormality and is associated with adverse outcomes in patients with AL amyloidosis (6) (7) (8) (9) (10) . However, it is unclear whether the rate of t (11;14) in patients with both AL amyloidosis and concurrent MM is similar to that in patients with AL amyloidosis alone. The present study aimed to examine the prevalence and clinical implications of t (11;14) in patients with AL amyloidosis with or without concurrent MM.
Methods
A total of 49 consecutive patients with newly diagnosed AL amyloidosis who were admitted to Kameda Medical Center (Chiba, Japan) from January 2008 to January 2018 were retrospectively analyzed. A diagnosis of AL amyloidosis was based on histological proof of amyloid deposition in the involved organ, abdominal fat and/or bone marrow biopsy specimen by staining with direct fast scarlet (DFS) and/or Congo-red with apple-green birefringence using crossed polarized light. The diagnosis of AL amyloidosis was further confirmed by immunohistochemistry and/or immunofluorescence of the kappa or lambda chain. Proteomic analysis with mass spectrometry was performed in selected cases. Monoclonal plasma cell proliferation was also studied by multicolor flow cytometry on aspirated bone marrow cells (11) . Patients were assessed for the presence of symptomatic MM according the International Myeloma Working Group criteria: bone marrow clonal plasma cells >10% and evidence of myeloma-defining events, including the CRAB criteria (12) . Patients with AL amyloidosis with >10% bone marrow plasma cells and any myeloma-defining events were described as having AL amyloidosis with MM (13) . Bone marrow plasma cell percentage was assessed by manual counts from either bone marrow aspirate smears or CD138 immunohistochemistry performed on bone marrow biopsy (14) . Hematological response was assessed according to consensus criteria for AL amyloidosis (15) , and hematological remission was defined as attaining very good partial response (10) . iFISH was performed according to the manufacturer's protocols at the Special Reference Laboratory (Hachiohji, Tokyo, Japan) using plasma cells purified by CD138-coated magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany). Written informed consent was obtained from all included patients. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Kameda Medical Center (Chiba, Japan).
Baseline characteristics were compared between the groups using Mann-Whitney U-test or Student's t-test for continuous variables and Fisher's exact test for categorical variables. Survival was analyzed by the Kaplan-Meier method and compared using the log-rank test. All statistical analysis was conducted using R version 3.1.2 (The R Foundation for Statistical Computing, Vienna, Austria). A twosided P value of <0.05 was considered statistically significant.
Results
The clinical characteristics of the patients in each group are summarized in the Table 1 . Nine patients were excluded owing to the unavailability of iFISH data. A total of 40 consecutive patients with AL amyloidosis were therefore analyzed. The median follow-up period was 13.6 months (range, 0.5-76.7 months). Seventeen (43%) patients with ≥10% bone marrow plasma cells had myelomadefining events according to the CRAB criteria, and these patients were considered to have AL amyloidosis with concurrent MM. Significant differences were observed in the proportion of patients with IgA type disease, the difference in involved and uninvolved light chains (dFLC), hemoglobin and estimated glomerular filtration rate. Other clinical parameters such as age, sex, Mayo 2012 staging, light chain type, albumin, alkaline phosphatase and calcium were not significantly different between the two groups.
The proportion of patients with t(11;14) as determined by iFISH was 40% (16/40) in our cohort. The prevalence of t(11;14) was significantly higher in patients with AL amyloidosis than in those with AL amyloidosis with MM. There were no significant differences in any other abnormalities, including t(4;14), del(17p), del(13q) and gain of 1q21. There were no cases of t(14;16) in either group.
Next, we analyzed the clinical characteristics of patients with AL amyloidosis with or without t (11;14) . Patients with t(11;14) had a significantly higher prevalence of the light-chain-only isotype (68.8%). Other clinical features were not significantly different between the two groups. The proportion of patients with hematological remission was 43.8% among patients with t(11;14) and 66.7% among those without t(11;14) (P = 0.20).
The Kaplan-Meier curves of overall survival (OS) in AL amyloidosis patients with or without concurrent MM are shown in Fig. 1A . The median OS was 60.6 months for patients without concurrent MM and 7.4 months for those with MM (P = 0.22). Thus, patients without concurrent MM experienced longer OS than those with MM, but the difference did not reach statistical significance due to the small number of patients. When patients were stratified based on the presence or absence of concurrent MM and t (11;14) , patients with t(11;14) tended to have shorter mean OS in both patient groups of amyloidosis alone and amyloidosis with concurrent MM [AL amyloidosis alone vs. AL amyloidosis + t(11;14): 60.6 vs. 32.7 months; AL amyloidosis + MM vs. AL amyloidosis + MM + t(11;14): 19.0 vs. 6.4 months, P = 0.09] (Fig. 1B) .
Discussion
Both AL amyloidosis and MM are plasma cell dyscrasias with distinct features from a clinical standpoint, but few studies have addressed the clinical and cytogenetic features of patients with AL amyloidosis and concomitant MM (3). This study investigated the prevalence of t(11;14), as detected by iFISH analysis, in AL amyloidosis patients with or without concurrent MM. The proportion of patients with t(11;14) in our cohort (40%) was similar to that in a previous report from the recent Mayo series (43%) (16) . We found that patients with concurrent MM exhibited lower prevalence of t (11;14) than patients with AL amyloidosis alone and that the presence of t(11;14) could adversely affect the prognosis of patients with AL amyloidosis, irrespective of the presence or absence of concurrent MM. Previous studies have shown that t(11;14) is the most common cytogenetic abnormality and is detected in~40-60% of patients with AL amyloidosis (10, 16, 17) . These studies, however, excluded patients with concomitant MM. Recently, Lakshman et al. (5) from the Mayo Clinic reported that the estimated prevalence of t (11;14) in patients with MM without AL amyloidosis was 33.3%, whereas in our study, the prevalence of t (11;14) in AL amyloidosis patients with or without concurrent MM was 17.6% and 56.5%, respectively. Furthermore, in line with their study, whereas the proportion of light-chain-only MM was significantly higher among MM patients with t(11;14) than among those without t (11;14) , in our study, the proportion of patients with light-chain-only MM was 68.8% in patients with t(11;14) compared to 12.5% in those without (P < 0.01). Therefore, it is possible that patients with lightchain-only monoclonal gammopathy of undetermined significance (MGUS) produce more pathogenic free light chain than those with other types of MGUS and that such patients develop symptoms of AL amyloidosis and die earlier, before the development of symptomatic MM, than those with MM with an intact immunoglobulin type. This pathophysiology may reflect the higher incidence of t (11;14) in patients with AL amyloidosis alone.
Patients with AL amyloidosis who had t(11;14) tended to have shorter OS, irrespective of the presence or absence of concurrent MM, in our series. Previous studies have shown that patients harboring t(11;14) have adverse outcomes in both AL amyloidosis and MM when treated with bortezomib-containing regimens (10) . In our cohort, almost all patients were treated with bortezomib-based regimens. The hematological remission rate in patients with t(11;14) was lower than that in patients without t(11;14), although the difference was not statistically significant. Thus, detection of t (11;14) may predict shorter OS in patients with AL amyloidosis, regardless of concomitant MM, when treated with bortezomibbased regimens.
Our study has several limitations. The first is the retrospective nature of the study design. Second, patient treatments varied considerably, but almost all patients were treated with bortezomibcontaining regimens. Third, although demonstration of characteristic green birefringence under polarizing microscope following Congo-red staining of biopsied tissue remains the gold standard for confirming deposition of amyloid, DFS staining is also used for identification of amyloid deposits. However, as DFS staining is not specific for AL amyloidosis, we performed Congo-red staining in cases positive for DFS staining for confirmation. In addition, proteomic analysis with mass spectrometry was performed on select cases. Finally, this study was performed at a single institute and, therefore, the sample size is small for sufficient statistical analysis. Therefore, additional multicenter studies using larger cohorts of patients are warranted.
In conclusion, this study demonstrates for the first time that patients with concurrent MM exhibit a lower prevalence of t(11;14) than those without MM among patients with AL amyloidosis. Moreover, the presence of t(11;14) was associated with a high prevalence of light-chain-only M-protein type, which could be associated with progression to light-chain amyloidosis owing to the relatively lower tumor burden.
